The future of microbial manufacturing: Chemically defined medium for protein and plasmid production Webinar

December 15, 2022

Video

This webinar highlights the development of the first chemically defined microbial medium. Designed to simplify workflows and achieve high density cultures, the Gibco™ Bacto™ CD Supreme supports advancements in therapeutics, gene therapy, and vaccine development. Discover data shared by experts and explore how you can improve process productivity and reduce risks.

Related Content

mainz,Rhineland-Palatinate /germany - 16 07 2022: the biontech company building and flags in mainz germany | Image Credit: © Tobias Arhelger - stock.adobe.com

CureVac to Be Acquired by BioNTech in $1.25B Deal to Advance mRNA Cancer Therapies

Christopher Cole

June 12th 2025

Article

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer immunotherapies.

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery

May 30th 2025

Podcast

In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.

Darmstadt, Germany - November 10, 2021: A building at the headquarters of science and technology company Merck KGaA. | Image Credit: © Anne Czichos - stock.adobe.com

MilliporeSigma and Simtra Launch Five-Year Agreement for Drug Substance, Drug Manufacturing Services

Patrick Lavery

June 11th 2025

Article

The agreement has been designed to offer a turnkey service to companies seeking faster time to market.

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific

March 28th 2025

Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

China’s NMPA Approves Merck KGaA Treatment for Tenosynovial Giant Cell Tumor

Patrick Lavery

June 10th 2025

Article

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with TGCTs that require systemic treatment.